

Paper No. \_\_\_\_  
Filed: December 14, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,  
INNOPHARMA INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS  
INC., and MYLAN INC.,  
Petitioner

v.

SENJU PHARMACEUTICAL CO., LTD., BAUCSH & LOMB, INC., and  
BAUSCH & LOMB PHARMA HOLDINGS CORP.,  
Patent Owner

---

Case IPR2015-00902  
U.S. Patent 8,669,290

---

**PATENT OWNER'S UPDATED EXHIBIT LIST**

Further to 37 C.F.R. § 42.63(e), Patent Owner Senju Pharmaceutical Co., Ltd., hereby submits a current listing of Senju Exhibits to counsel for Petitioner InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., InnoPharma LLC, Mylan Pharmaceuticals Inc., and Mylan Inc..

<b>Exhibits</b>	<b>Description</b>
Exhibit 2001	Transcript of Teleconference with the Board, dated April 15, 2015.
Exhibit 2002	U.S. Patent No. 8,669,290 to Sawa <i>et al.</i> , "Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid."
Exhibit 2003	U.S. Patent No. 8,754,131 to Sawa <i>et al.</i> , "Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid."
Exhibit 2004	U.S. Patent No. 8,871,813 to Sawa <i>et al.</i> , "Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid."
Exhibit 2005	U.S. Patent No. 8,927,606 to Sawa <i>et al.</i> , "Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid."
Exhibit 2006	InnoPharma's Paragraph IV Notice Letter dated September 19, 2014.
Exhibit 2007	InnoPharma's Paragraph IV Notice Letter dated October 30, 2014.
Exhibit 2008	InnoPharma's Paragraph IV Notice Letter dated March 27, 2015.
Exhibit 2009	Complaint, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No. 14-cv-06893 (D.N.J. Nov. 3, 2014), ECF No. 1.
Exhibit 2010	Complaint, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No.15-cv-03240 (D.N.J. May 8, 2015), ECF No. 1.
Exhibit 2011	Consolidated scheduling order, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No. 14-cv-06893

	(D.N.J. April 16, 2015), ECF No. 30.
Exhibit 2012	Amended scheduling order, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-00667 (D.N.J. Feb. 27, 2015), ECF No. 63.
Exhibit 2013	Prolensa® (bromfenac ophthalmic solution 0.07%) Prescribing Information.
Exhibit 2014	U.S. Patent No. 5,630,793 to Rowe, “Aqueous Ophthalmic Sprays.”
Exhibit 2015	Press Release by Bausch + Lomb, dated April 8, 2013, entitled “Bausch + Lomb Receives FDA Approval for Prolensa™ (bromfenac ophthalmic solution) 0.07%.”
Exhibit 2016	Lupin’s Paragraph IV Notice Letter dated March 13, 2014.
Exhibit 2017	Metrics’ Paragraph IV Notice Letter dated June 26, 2014.
Exhibit 2018	Paddock’s Paragraph IV Notice Letter dated December 15, 2014.
Exhibit 2019	Apotex’s Paragraph IV Notice Letter dated December 10, 2014.
Exhibit 2020	Masson et al., <i>Stabilisation of ionic drugs through complexation with non-ionic and ionic cyclodextrins</i> , INT’L JOURNAL OF PHARMACEUTICS 164 (1998).
Exhibit 2021	Loftsson et al., <i>Pharmaceutical Applications of Cyclodextrins</i> , JOURNAL OF PHARMACEUTICAL SCIENCES 85:10 (1996).
Exhibit 2022	HSBC Global Research Lupin Company Report, February 3, 2014, <a href="http://www.lupin.com/pdf/14/20140203%20-%20Lupin%203QFY14%20-%20HSBC.pdf">http://www.lupin.com/pdf/14/20140203%20-%20Lupin%203QFY14%20-%20HSBC.pdf</a>
Exhibit 2023	APOTEX ALL PRODUCTS, <a href="https://www.apotex.com/us/en/products/search.asp?qt=All&amp;qs=&amp;t=All%20Products">https://www.apotex.com/us/en/products/search.asp?qt=All&amp;qs=&amp;t=All%20Products</a> .
Exhibit 2024	Consent judgment, <i>Senju Pharm. Co., Ltd. et al. v. Apotex Inc. et al.</i> , No. 15-cv-00336 (D.N.J. May 18, 2015), ECF No. 26.
Exhibit 2025	U.S. Patent No. 5,856,345 to Doi et al., “Method for Stabilizing Pranoprofen and Stable Liquid Preparation of Pranoprofen.”
Exhibit 2026	Xibrom® Prescribing Information.

Exhibit 2027	Bromday® Prescribing Information.
Exhibit 2028	Drugs@FDA, Listing of FDA-approved bromfenac ophthalmic solution 0.09% products, <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=BROMFENAC%20SODIUM">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=BROMFENAC%20SODIUM</a> .
Exhibit 2029	Sheryl Gay Stolberg, <i>New Painkiller is Withdrawn After 4 Deaths</i> , N.Y. Times, Jun. 23, 1998.
Exhibit 2030	Baklayan et al., <i>The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model</i> , CLINICAL OPHTHAMOLOGY 2014:8, 1717-1724 (2014).
Exhibit 2031	Reserved
Exhibit 2032	Reserved
Exhibit 2033	Reserved
Exhibit 2034	Reserved
Exhibit 2035	Transcript of Teleconference with the Board, dated December 11, 2015

Respectfully submitted,

Dated: December 14, 2015

By: /Bryan C. Diner/  
Bryan C. Diner, Lead Counsel  
Reg. No. 32,409  
Finnegan, Henderson, Farabow, Garrett  
& Dunner, L.L.P.  
901 New York Ave. NW  
Washington, DC 20001-4413

*Counsel for Patent Owner*

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that a copy of the foregoing **Patent Owner's Updated Exhibit List and Exhibit 2035** were served on December 14, 2015, via email directed to counsel of record for the Petitioner at the following:

Jitendra Malik  
jitty.malik@alston.com

Bryan Skelton  
bryan.skelton@alston.com

Lance Soderstrom  
[lance.soderstrom@alston.com](mailto:lance.soderstrom@alston.com)

Hidetada James Abe  
James.abe@alston.com

Date: December 14, 2015

/Ashley F. Cheung/  
Ashley F. Cheung  
Case Manager

Finnegan, Henderson, Farabow, Garrett &  
Dunner, LLP